|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients显示文摘Background:Hepatocellular carcinoma(HCC)is one of the most common causes of cancer worldwide.Although many studies have focused on oncogene characteristics,the genomic landscape of Chinese HCC patients has not been fully clarified.Methods:A total of 165 HCC patients,including 146 males and 19 females,were enrolled.The median age was 55 years(range,27-78 years).Corresponding clinical and pathological information was collected for further analysis.A total of 168 tumor tissues from these patients were selected for next-generation sequencing(NGS)-based 450 panel gene sequencing.Genomic alterations including single nucleotide variations(SNV),short and long insertions and deletions(InDels),copy number variations,and gene rearrangements were analyzed.Tumor mutational burden(TMB)was measured by an algorithm developed in-house.The top quartile of HCC was classified as TMB high.Results:A total of 1,004 genomic alterations were detected from 258 genes in 168 HCC tissues.TMB values were identified in 160 HCC specimens,with a median TMB of 5.4 Muts/Mb(range,0-28.4 Muts/Mb)and a 75%TMB of 7.7 Muts/Mb.The most commonly mutated genes were TP53,TERT,CTNNB1,AXIN1,RB1,TSC2,CCND1,ARID1A,and FGF19.SNV was the most common mutation type and C:G>T:A and guanine transformation were the most common SNVs.Compared to wild-type patients,the proportion of Edmondson grade III-IV and microvascular invasion was significantly higher in TP53 mutated patients(P<0.05).The proportion of tumors invading the hepatic capsule was significantly higher in TERT mutated patients(P<0.05).The proportion of Edmondson grade I-II,alpha fetoprotein(AFP)<25μmg/L,and those without a history of hepatitis B was significantly higher in CTNNB1 mutated patients(P<0.05).CTNNB1 mutations were associated with TMB high in HCC patients(P<0.05).Based on correlation analysis,the mutation of TP53 was independently correlated with microvascular invasion(P=0.002,OR=3.096)and Edmondson grade III-IV(P=0.008,OR=2.613).The mutation of TERT was independently correlated with tumor invasion of the liver capsule(P=0.001,OR=3.030),and the mutation of CTNNB1 was independently correlated with AFP(<25μmg/L)(P=0.009,OR=3.414).Conclusions:The most frequently mutated genes of HCC patients in China were TP53,TERT,and CTNNB1,which mainly lead to the occurrence and development of HCC by regulating the P53 pathway,Wnt pathway,and telomere repair pathway.There were more patients with microvascular invasion and Edmondson III-IV grade in TP53 mutated patients and more patients with hepatic capsule invasion in TERT mutated patients,while in CTNNB1 mutated patients,there were more patients with Edmondson I-II grade,AFP<25μmg/L,and a non-hepatitis B background.Also,the TMB values were significantly higher in CTNNB1 mutated patients than in wild type patients. | Shuo Wang Huasheng Shi Tao Liu Manjiang Li Sanshun Zhou Xuan Qiu Zusen Wang Weiyu Hu Weidong Guo Xiaoqian Chen Honglin Guo Xiaoliang Shi Junping Shi Yunjin Zang Jingyu Cao Liqun Wu | 2021 | Hepatobiliary Surgery and Nutrition2021，10，2： | 8 |
| 2 | Targeted therapy for hepatocellular carcinoma显示文摘The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma(HCC).Sorafenib has been the mainstay of treatment for a decade and newer modalities were ineffective and did not confer any increased therapeutic benefit until the introduction of lenvatinib which was approved based on its non-inferiority to sorafenib.The subsequent success of regorafenib in HCC patients who progress on sorafenib treatment heralded a new era of second-line treatment and was quickly followed by ramucirumab,cabozantinib,and the most influential,immune checkpoint inhibitors(ICIs).Over the same period combination therapies,including anti-angiogenesis agents with ICIs,dual ICIs and targeted agents in conjunction with surgery or other loco-regional therapies,have been extensively investigated and have shown promise and provided the basis for exciting clinical trials.Work continues to develop additional novel therapeutic agents which could potentially augment the presently available options and understand the underlying mechanisms responsible for drug resistance,with the goal of improving the survival of patients with HCC. | Ao Huang Xin-Rong Yang Wen-Yuan Chung Ashley R.Dennison Jian Zhou | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 7 |
| 3 | miR-132、GPC3在乙肝相关肝癌患者中的表达及意义显示文摘目的研究乙肝相关肝癌患者血清中miR-132、GPC3表达水平及其临床意义。方法前瞻性选取2015年2月至2017年2月我院就诊的53例乙肝相关肝癌患者(乙肝相关肝癌组)、49例乙肝肝硬化患者(乙肝肝硬化组)、31例乙型肝炎患者(乙肝组)及40例健康体检者(健康对照组)作为研究对象。检测四组受试者血清中miR-132、GPC3水平,分析miR-132、GPC3与乙肝相关肝癌患者临床病理资料的关系及其在预判乙肝相关肝癌患者预后和临床疗效评估中的价值。结果乙肝相关肝癌组、乙肝肝硬化组、乙肝组和健康对照组血清miR-132、GPC3水平比较,均差异有统计学意义(均P<0.05)。乙肝相关肝癌组患者血清miR-132浓度为[1.2(1.0,1.5)],低于乙肝肝硬化组、乙肝组和健康对照组,血清GPC3浓度为(1.8±0.7) ng/mL,高于乙肝肝硬化组、乙肝组和健康对照组,均差异有统计学意义(均P<0.05)。乙肝相关肝癌患者血清miR-132表达水平与肿瘤分化程度、TNM分期、甲胎蛋白水平和门静脉癌栓有关(P<0.05)。血清GPC3表达与患者性别、年龄、肿瘤直径、分化程度、TNM分期、甲胎蛋白水平和门静脉癌栓均不相关(P>0.05)。乙肝相关肝癌患者治疗后,血清miR-132水平较治疗前升高[3.8(1.9,5.5)对1.1(0.9,1.4)], GPC3水平较治疗前降低[(1.4±0.3)对(1.8±0.7) ng/mL],均差异有统计学意义(均P<0.05)。53例乙肝相关肝癌患者1年内存活40例,占75.5%。生存组患者血清miR-132表达水平高于死亡组[1.2(1.0,2.0)对0.9(0.7,1.1)],血清GPC3水平低于死亡组[(1.7±0.6)对(2.2±0.8) ng/mL],均差异有统计学意义(均P<0.05)。miR-132和GPC3联合诊断预判乙肝相关肝癌患者预后的效能高于单独诊断(P<0.05)。结论联合检测乙肝相关肝癌患者血清miR-132、GPC3水平,可有助于患者的预后判断和治疗作用评估。 | 杨启 吕新远 王哲 | 2019 | 肝脏2019，24，2： | 3 |
| 4 | 肝癌微环境时空异质性与个体化免疫治疗显示文摘肿瘤免疫微环境(tumor immune microenvironment,TIME)是一个高度复杂的生态系统,肿瘤细胞与免疫细胞在时间、空间维度动态互作,产生时空异质性(spatiotemporal heterogeneity)。值得注意:肝癌免疫微环境异质性与临床表型显著相关;抗原呈递、趋化因子、免疫代谢等相关机制参与了免疫微环境异质性的时空调控。未来,随着研究工具不断进步、对时空异质性解析逐渐深入,基于个体免疫微环境动态特征,建立个体化免疫治疗(personalized immunotherapy)新策略,将使更多肿瘤患者获益。 | 成怡斐 高强 | 2022 | 中国细胞生物学学报2022，44，4： | 2 |
| 5 | 单细胞测序技术在肝癌研究中的应用显示文摘传统的细胞遗传信息研究方法是对大量混合细胞进行高通量测序,得到一群细胞基因表达的平均值,忽视了细胞间存在的异质性。肝癌作为一种人类常见的恶性致命肿瘤,其内部肿瘤细胞存在高度异质性,群体水平分析无法精确揭示其恶性细胞克隆结构和免疫微环境的细胞种类、状态和亚群分布,因此迫切需要进行单细胞水平的分析,这将有助于深入了解肝癌发病机制,进行精准肝癌分型指导临床治疗。同时发现,新型治疗靶点及有效生物标记物,为肝癌患者今后进行精准诊疗提供参考。本文综述了单细胞基因组和转录物组测序技术在肝癌免疫微环境、肝癌细胞异质性、肝癌细胞演化与诊疗和肝癌转移机制及生物标志物研究中的应用。本文还总结了在肝癌研究中,单细胞多组学测序技术在发现新肿瘤亚群、精确识别肿瘤细胞间的异质性和了解肿瘤微环境构成等方面的优势。 | 王娜 赵利楠 韩泽广 | 2020 | 中国生物化学与分子生物学报2020，36，5： | 2 |
| 6 | 卵巢巨大实性成熟型畸胎瘤伴腹膜神经胶质瘤病一例显示文摘畸胎瘤约占卵巢肿瘤的20%,其中99%卵巢畸胎瘤为成熟畸胎瘤.不同于未成熟畸胎瘤,成熟畸胎瘤多以囊性为主,成熟型实性畸胎瘤罕见.腹膜神经胶质瘤病(gliomatosis peritonei, GP)是以腹膜内成熟神经胶质结节为特征的病变,常与卵巢畸胎瘤(尤其不成熟畸胎瘤)有关,属于非常少见的一类疾病.GP多发生于10~20岁,多与体积较大畸胎瘤伴发,其成分以神经为主,主要分布于畸胎瘤周围腹膜及大网膜.该病例为37岁女性卵巢肿瘤患者,术前及术中临床及影像学提示卵巢癌可能.经充分取材,术后病理诊断为卵巢巨大实性成熟型畸胎瘤伴GP. | 马倩 韦富美 吴擎智 郑建明 | 2019 | 中华病理学杂志2019，48，8： | 2 |
| 7 | 单细胞测序技术及其在肝脏疾病研究中的应用显示文摘近几年来,单细胞测序作为新兴的测序技术,可以从单个细胞的层面解析细胞的基因组和转录组等,突破了以往实验技术的瓶颈,能够反映细胞间的异质性,从而有利于揭示疾病发生发展的机制。肝脏是人体中重要的代谢器官,并在人体的脱氧、糖原储存和分泌蛋白的合成中发挥作用。肝脏在病原体感染、药物、代谢紊乱的影响下容易产生肝炎,炎症持续状态下肝脏机能有可能逐渐恶化导致肝硬化或肝癌等疾病。近几年来,单细胞测序技术在肝病研究中的应用日益增多。本文综述了单细胞测序技术在肝脏生理功能以及若干肝脏疾病中的最新研究进展,以期有助于今后肝病的基础科研以及指导临床肝病的诊治。 | 王煜鹏 杨扬 王学军 周喆 王升启 | 2020 | 生物技术通讯2020，31，2： | 1 |
| 8 | 多结节性肝细胞癌起源及治疗策略显示文摘肝细胞癌(HCC)是一种原发于肝脏的恶性肿瘤,是世界范围内最常见的五大恶性肿瘤之一,其病死率也高居全球癌症的第四位[1]。大多数HCC患者主要分布在亚洲和非洲,大部分与病毒感染(HBV或HCV)有关。2015年我国HCC发病率在中国癌症数据中排名第四,癌症致死率排名第三,每年我国新诊断HCC和死于HCC的患者40余万例,发病及死亡人数约占世界的一半[2]。我国HCC具有发病率高、诊断晚、病死率和复发率高等特点,预后较差。 | 张剑文 李华 | 2022 | 中华肝脏外科手术学电子杂志2022，11，4： | 1 |
| 9 | 单细胞测序技术在肿瘤中的研究进展显示文摘肿瘤异质性是恶性肿瘤的特征之一,单细胞测序技术是在单个细胞水平上进行全基因组、转录组以及表观遗传学测序,从而为肿瘤异质群体的细胞亚群分类提供依据,进而有效揭示肿瘤细胞内有关遗传、转录和表观遗传水平复杂性改变的过程。本文介绍测序技术的进展、单细胞测序技术方法以及单细胞测序技术在具体肿瘤中的应用进展,并对其发展前景进行了展望。 | 邓南星 白雪 张志伟 | 2022 | 中南医学科学杂志2022，50，5： | 1 |
| 10 | HBsAg动态监测对HBV相关性肝细胞癌患者根治性切除术后生存的预测作用显示文摘目的探讨乙型肝炎病毒(HBV)相关性肝细胞癌(HCC)患者在接受根治性切除术前后血清乙肝病毒抗原(HBsAg)水平变化对预后的预测作用。方法回顾性分析165例接受根治性切除治疗的HBV相关性HCC患者的临床资料并进行随访。根据术前或术后血清HBsAg水平将患者分为HBsAg高水平组(>200 ng/ml)及HBsAg低水平组(≤200 ng/ml)。采用Kaplan-Meier及Log-rank检验比较患者总生存率(OS)和无复发生存率(RFS)差异。采用Cox多因素风险模型对影响患者预后的危险因素进行分析。结果术前HBsAg低水平组与高水平组的1年OS分别为90.5%、85.3%,3年OS分别为78.0%、70.6%,差异有统计学意义(P<0.05);1年RFS分别为72.3%、67.2%,3年RFS分别为60.8%、50.6%,差异有统计学意义(P<0.05)。术后血清HBsAg低水平组与高水平组的1年OS分别为92.6%、88.6%,3年OS分别为80.9%比、72.8%,差异有统计学意义(P<0.05);但两组患者的1年RFS分别为68.3%、72.1%,3年RFS分别为50.6%、45.0%,差异无统计学意义(P>0.05)。术后HBsAg上升组与下降组的1年RFS分别为74.1%、73.6%,3年RFS分别为51.1%、57.5%,差异无统计学意义(P>0.05);术后1年OS分别为86.3%、94.9%,3年OS分别为72.8%、84.8%,差异有统计学意义(P<0.05)。风险因素分析显示,是否接受抗病毒治疗、HBsAg水平、谷草转氨酶(AST)、甲胎蛋白(AFP)及肿瘤直径是影响患者OS的独立性因素(P<0.05)。是否接受抗病毒治疗、HBsAg、AST、谷丙转氨酶(ALT)、AFP及肿瘤直径是影响患者RFS的独立性因素(P<0.05)。结论血清HBsAg水平可作为预测接受根治性肝切除术后肝癌患者预后的潜在指标,手术前后的HBsAg水平越低,患者预后越好。 | 曾淑英 唐丹 袁进 吕敏 刘非 | 2022 | 四川医学2022，43，2： | 1 |
| 11 | 11C-乙酸盐PET/CT显像对肝细胞癌的辅助诊断价值显示文摘目的探讨C-乙酸盐PET/CT局部显像对肝细胞癌(HCC)的辅助诊断价值,并与CT增强扫描进行对比。资料与方法对2015年6月—2021年1月于贵州医科大学附属医院核医学科经F-FDG PET/CT全身显像呈阴性、临床疑诊为肝脏肿瘤样病变的23例患者(其中伴乙型病毒性肝炎肝硬化病史22例,甲胎蛋白升高12例)进行回顾性分析,均行F-FDG及C-乙酸盐PET/CT显像,分析图像并收集其临床资料,计算双核素PET/CT显像及CT增强的敏感度、特异度等诊断效能指标。结果最终诊断为HCC 13例,诊断为非HCC 10例。在诊断为HCC的13例中,4例经病理证实均为中分化HCC,9例经临床随访15个月以上临床确诊为HCC。诊断为非HCC的10例中,1例经病理证实,9例经临床随访15个月以上临床确诊。23例均行C-乙酸盐局部显像,其对HCC的诊断敏感度、特异度、约登指数、阳性预测值、阴性预测值及准确度分别为84.6%、100%、0.846、100%、83.3%、91.3%。结论C-乙酸盐PET/CT局部显像对于分化程度较高的HCC可作为补充检查进行联合显像,弥补F-FDG在诊断中、高分化HCC方面的不足,提高定性诊断的准确度。 | 包惠桢 宋普姣 谢晓菲 | 2022 | 中国医学影像学杂志2022，30，8： | 1 |
| 12 | 分子生物学技术鉴别多结节肝癌克隆起源的研究进展显示文摘肝细胞癌(肝癌)类型不同,选择治疗的方式及预后也不同。其中,多结节肝癌按起源分为多中心起源和肝内转移,这两种类型肝癌有不同的肿瘤生物学特性,而如何确定其类型是选择治疗方式的前提。分子生物学技术可用于区分这两种类型的多结节肝癌。目前,鉴别多结节肝癌的常用分子生物学技术包括乙型肝炎病毒DNA整合方式、p53基因突变类型、甲胎蛋白基因低甲基化分析、线粒体DNA D-环区突变分析、比较基因组杂交技术、蛋白组学技术、下一代测序技术。 | 赵媛 罗洪林 刘军杰 陈苗 黎乐群 | 2019 | 山东医药2019，59，1： | 1 |
| 13 | scDPN for High-throughput Single-cell CNV Detection to Uncover Clonal Evolution During HCC Recurrence显示文摘Single-cell genomics provides substantial resources for dissecting cellular heterogeneity and cancer evolution.Unfortunately,classical DNA amplification-based methods have low throughput and introduce coverage bias during sample preamplification.We developed a single-cell DNA library preparation method without preamplification in nanolitre scale(scDPN)to address these issues.The method achieved a throughput of up to 1800 cells per run for copy number variation(CNV)detection.Also,our approach demonstrated a lower level of amplification bias and noise than the multiple displacement amplification(MDA)method and showed high sensitivity and accuracy for cell line and tumor tissue evaluation.We used this approach to profile the tumor clones in paired primary and relapsed tumor samples of hepatocellular carcinoma(HCC).We identified three clonal subpopulations with a multitude of aneuploid alterations across the genome.Furthermore,we observed that a minor clone of the primary tumor containing additional alterations in chromosomes 1q,10q,and 14q developed into the dominant clone in the recurrent tumor,indicating clonal selection during recurrence in HCC.Overall,this approach provides a comprehensive and scalable solution to understand genome heterogeneity and evolution. | Liang Wu Miaomiao Jiang Yuzhou Wang Biaofeng Zhou Yunfan Sun Kaiqian Zhou Jiarui Xie Yu Zhong Zhikun Zhao Michael Dean Yong Hou Shiping Liu | 2021 | Genomics, Proteomics & Bioinformatics2021，19，3： | 1 |
| 14 | miR-26a-5p影响肝癌细胞迁移和侵袭的机制研究显示文摘目的探讨微小RNA-26a-5p(miR-26a-5p)对腹水来源的高转移人肝癌细胞系SK-HEP-1生物学行为的影响及机制。方法采用实时荧光定量PCR(qRT-PCR)检测比较人正常肝细胞LO2及不同人肝癌细胞系(HepG2、BEL-7402、SMMC-7721、MHCC97H和SK-HEP-1)中miR-26a-5p和IL-6 mRNA的表达水平。选择低表达水平的SK-HEP-1细胞转染miR-26a-5p模拟物,采用qRT-PCR法和ELISA法检测转染后细胞中miR-26a-5p、IL-6 mRNA的表达水平和IL-6的分泌情况。划痕和Transwell实验检测miR-26a-5p对SK-HEP-1细胞转移和侵袭能力的影响。双荧光素酶报告基因检测miR-26a-5p与IL-63'-非编码区(UTR)的靶向结合关系。Western blot法检测miR-26a-5p对SK-HEP-1细胞中信号转导和转录激活因子3(STAT3)蛋白磷酸化和上皮-间质转化(EMT)相关蛋白的表达变化。采用qRT-PCR法检测miR-26a-5p对EMT相关基因表达水平的影响。结果与LO2相比,人肝癌细胞中miR-26a-5p相对表达量明显下调,IL-6 mRNA相对表达量明显上调,其中SKHEP-1中相对表达量差异最为显著。miR-26a-5p模拟物转染SK-HEP-1细胞后,miR-26a-5p相对表达量显著增高,IL-6 mRNA和蛋白相对表达量显著下调。双荧光素酶报告基因实验证实miR-26a-5p与IL-63'-UTR存在序列特异性靶向结合关系。与空白对照组和模拟物对照组相比,miR-26a-5p模拟物明显抑制SK-HEP-1细胞迁移和侵袭的能力,同时显著降低IL-6下游信号STAT3蛋白的磷酸化水平,升高E-钙黏蛋白相对表达量和降低波形蛋白相对表达量。与模拟物对照组相比,miR-26a-5p模拟物显著改变EMT相关基因表达。结论miR-26a-5p通过靶向抑制IL-6 mRNA,下调STAT3磷酸化,调控肝癌EMT标志物的基因和蛋白水平的表达,从而逆转肝癌细胞SK-HEP-1迁移和侵袭。 | 范巍巍 曹萌 魏清筠 | 2023 | 浙江医学2023，45，9： | 0 |
| 15 | 基于高压水动力注射基因转染法构建小鼠原发性肝癌模型的方法及研究进展显示文摘原发性肝癌发病率和死亡率不断上升,在预防、诊断和治疗方面对全球健康提出了更高挑战。建立原发性肝癌动物模型是筛选潜在治疗靶点和开展临床前研究的必要条件。基于高压水动力注射基因转染法构建小鼠原发性肝癌模型具有可靠、快速、灵活和节约成本等优势,为更好地了解人类肝癌的分子发病机制,测试抗肝癌药物的治疗潜力等提供了有效途径,近二十年来逐渐被研究者们应用。本文以高压水动力注射基因转染构建小鼠原发性肝癌模型的基本原理为切入点,综述该模型的具体构建方法及其近年来的研究进展,以期为原发性肝癌的临床前研究提供有价值的参考。 | 洪昕 高铭舒 许小君 魏元元 李小磊 黄启超 | 2022 | 中国癌症防治杂志2022，14，4： | 0 |
| 16 | 多灶肝细胞癌异质性的多组学研究与临床意义显示文摘超过一半的肝细胞癌(HCC)患者在就诊时肝内已出现多发病灶,临床上针对多灶HCC的治疗手段十分有限且疗效不佳。多灶HCC中肿瘤的高度异质性是导致治疗失败的重要原因。越来越多的研究采用多组学测序,探索多灶HCC中不同病灶间的基因水平和转录水平的异质性,包括肿瘤克隆进化以及基因突变、拷贝数变异、结构变异、RNA表达、肿瘤免疫微环境特征等的异质性。肿瘤克隆进化导致的药物靶点分布以及免疫微环境的特征可精准预测多灶HCC患者对靶向药物和免疫治疗的疗效。因此,全面、准确地评估多灶HCC的多组学异质性对实施精准治疗至关重要。 | 匡铭 许丽霞 刘信 章颖 沈顺利 | 2020 | 临床肝胆病杂志2020，36，10： | 0 |
| 17 | Personalized T-cell therapy in liver transplanted patients with hepatitis B virus related hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC)is a deadly malignancy which typically occurs in the context of chronic liver inflammation.Chronic hepatitis B virus(HBV)infection is considered a major global cause of HCC development.At the moment,liver transplantation is the only curative modality for HBV-associated HCC.However,some patients develop HBV-HCC recurrence after liver transplantation,leaving them with very limited therapeutic options.Adoptive cell therapy with HBV-specific T cell receptor(TCR)that redirects T cells against HCC relapses has shown promising results in such HBV-HCC patients.In this mini-review,we discuss the application of this personalized T cell therapy,and highlight mRNA electroporation as an efficient tool for engineering safe and efficient TCR-redirected T cells for the treatment of liver transplant patients with HBV-HCC metastasis. | Morteza Hafezi Antonio Bertoletti Anthony Tan | 2020 | Hepatoma Research2020，6，5： | 0 |
| 18 | Mechanisms and immunotherapies of HBV- and NAFLD-related hepatocellular carcinoma显示文摘Hepatitis B virus(HBV)infection remains the most important risk factor for hepatocellular carcinoma(HCC)worldwide and nonalcoholic fatty liver disease(NAFLD)has developed as major etiology of chronic liver diseases,cirrhosis and eventually HCC in the last decades.Although nucleos(t)ide analogs are recommended as the first-line drug for patients with chronic hepatitis B,incomplete eradication of HBV serves as an obstacle for effective cure of chronic hepatitis B and even HCC.NAFLD refers to a spectrum of hepatic metabolic disorders,compromised with multi-system diseases.Considering the specificity of hepatocytes and enrichment of immune cells in liver,this review aims to summarize the mechanisms of direct pro-tumorigenesis to hepatocytes induced by HBV infection and abnormal lipid metabolism,and indirect oncogenic processes mediated by immune cells.We also discuss similarities and differences of immune cells between HBV-and NAFLD-HCC and finally focus on the novel immunotherapies concerning preclinical and clinical studies for liver cancer. | Xiao-Jia Song Chun-Hong Ma | 2020 | Hepatoma Research2020，6，5： | 0 |
| 19 | 哺乳动物单细胞研究技术的现状与未来显示文摘近年来,生命科学和医学的基础研究已深入到单细胞阶段。单细胞研究为揭示生命活动的基本规律、探索细胞异质性、提高对疾病发病机制的认识等提供了重要的线索和依据,同时,单细胞技术已被应用于日常实践中,如法医学和临床生殖医学。单细胞研究中使用的技术也在不断变化,并越来越复杂。文中主要介绍单细胞分离技术,包括手工挑取、激光捕获显微切割和微流控技术,以及单细胞中DNA、RNA和蛋白质分析方法的各种技术。此外,文中总结了近年来生命科学和医学领域的主要单细胞研究成果,讨论了单细胞相关技术和研究的不足,并介绍了其未来的发展方向。 | 姜文倩 田亚茸 左锐 林峻 | 2019 | 生物工程学报2019，35，1： | 0 |
| 20 | Profile of Dr. Jia Fan显示文摘Dr.Jia Fan,MD,is the President of Zhongshan Hospital,Professor at the Department of Liver Surgery,Chairman of the Shanghai Association of Liver Disease,and Deputy Chief of the Liver Cancer Institute at Fudan University.He received his MS degree from Medical College of Southeast University in 1988 and PhD degree from Shanghai Medical College of Fudan University in 1995.He was a Visiting Scholar at the University of Pittsburgh Medical Center from 1999 to 2000.Further,his cancer research has earned him elections as an Academician of the Chinese Academy of Sciences in 2017,the Chairman of the Oncology Branch of Chinese Medical Association in 2014,and a Fellow of the American College of Surgeons in 2007.He has been the Chairman of the Chinese Society of Liver Cancer and the Oncology Branch of the Shanghai Medical Association.In addition,he has been a peer reviewer for many prestigious international journals such as The Lancet,Journal of Clinical Oncology,and Oncogene.Dr.Jia Fan has dedicated his career to clinical diagnosis,treatment,and basic research of liver cancer.His major contributions to the field are described below. | | 2019 | Science China(Life Sciences)2019，62，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员